Abstract library

2116 results for "advanced non-resectable neuroendocrine neoplams".
#2954 Aggressive Resection - A Treatment Option in Patients with Advanced Neuroendocrine Tumors
Introduction: Different treatment modalities have been considered for patients with malignant advanced neuroendocrine tumors(NETs) of the pancreas and duodenum.Aggressive surgery remains a controversial yet an efficacious antitumor therapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Doctor Azka Athar
Authors: Athar A
#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)
Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Minseok Suh
Authors: Suh M, Cheon G J, Lee D S
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
#2773 Impact on Outcome in Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) Included in Prospective Clinical Trials (CT)
Introduction: Access to CT offers cancer pts the opportunity to receive new treatments and better monitoring of efficacy and toxicity. The increase of systemic therapy options in advanced NENs has relegated the inclusion of pts in CT to later lines of treatment as suggested in most guidelines.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD PhD Jorge Hernando-Cubero
#2847 Surgical and Survival Outcomes of Early Peptide Receptor Radionuclide Therapy for Downstaging Locally Advanced or Oligometastatic Pancreatic Neuroendocrine Neoplasms
Introduction: Pancreatic neuroendocrine neoplasm (pNEN) patients often present with locally advanced or metastatic disease. The objective response rate of peptide receptor radionuclide therapy (PRRT) in pNENs is 55%. Therefore, PRRT may be a possibility for patients who are not eligible for upfront curative surgery.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Noémie S Minczeles
#2914 Safety Profile and Adverse Events of Special Interest for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial
Introduction: The previously reported SANET-ep trial (NCT02588170) demonstrated surufatinib significantly improves progression-free survival (PFS) in patients (pts) with advanced extrapancreatic neuroendocrine tumors (epNETs) compared to placebo; median PFS (9.2 vs. 3.8 months; HR = 0.334, 95% CI 0.223 to 0.499, p
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Jie Li
Authors: Li J, Xu J, Zhou Z, Bai C, ...
#2924 Everolimus in Patients with Advanced Neuroendocrine Neoplasia: A Real-World Study and Analysis of Long Responders
Introduction: Everolimus is a valid therapeutic option for neuroendocrine tumors (NETs); however, data regarding the long responsders in a real-world setting, outside regulatory trials, are scanty.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Maria Rinzivillo
#2690 Marked Response to Nab-Paclitaxel in Advanced Neuroendocrine Carcinoma of Nasal Sinuses: A Case Report
Introduction: Sinonasal neuroendocrine carcinomas (SNECs) are a very rare and high-grade malignant epithelial neoplasm that is usually associated with a poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Zhirong Qi
Authors: Qi Z, Zhang Y, Li Y, Wang C, ...
#2723 Achieving Objective Response in Treatment of Non-Resectable Neuroendocrine Tumors Does Not Predict Longer Time to Progression Compared to Achieving Stable Disease
Introduction: There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally the goal of these treatments are to reduce the tumor load; objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without reduction in total tumor load; stable disease (SD).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Espen Thiis-Evensen
Authors: Thiis-Evensen E, Sponheim J, ...
#2240 CT-Guided HDR Brachyterapy in Patients with Advanced Non-Resectable and Progressive NEN with Liver Bulky Disease. Pilot Study
Introduction: CT-Guided HDR Brachyterapy is a new method used for liver metastases treatment.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dariusz Kieszko